Standard BioTools Inc.

NasdaqGM:SLGC Stock Report

Market Cap: US$396.2m

Standard BioTools Future Growth

Future criteria checks 1/6

Standard BioTools is forecast to grow earnings and revenue by 8.1% and 16.4% per annum respectively while EPS is expected to grow by 4.8% per annum.

Key information

8.1%

Earnings growth rate

4.8%

EPS growth rate

Life Sciences earnings growth18.8%
Revenue growth rate16.4%
Future return on equityn/a
Analyst coverage

Low

Last updated04 Jan 2024

Recent future growth updates

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Nov 10
SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Recent updates

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

Dec 19
Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Nov 10
SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Apr 17
SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Apr 02
Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

SomaLogic appoints former Foundation Medicine chief as executive chair

Oct 17

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

Jul 26

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Jun 06
We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

Apr 12

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

Mar 09
Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Dec 28
We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Oct 14

Earnings and Revenue Growth Forecasts

NasdaqGM:SLGC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026140-69N/A-812
12/31/2025118-84N/A-872
12/31/202499-100N/A-914
12/31/202384-111N/A-1134
9/30/202382-130-122-117N/A
6/30/2023101-141-139-134N/A
3/31/202395-139-144-138N/A
12/31/202298-109-106-101N/A
9/30/2022102-83-96-92N/A
6/30/202280-92-75-70N/A
3/31/202286-82-46-42N/A
12/31/202182-88-44-40N/A
9/30/202187-73-27-23N/A
6/30/202181-39-13-11N/A
3/31/202168-45-22-21N/A
12/31/202056-53-29-28N/A
12/31/201932-57-51-51N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLGC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SLGC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SLGC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SLGC's revenue (16.4% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: SLGC's revenue (16.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SLGC's Return on Equity is forecast to be high in 3 years time


Discover growth companies